摘要
目的 探讨拉米夫定治疗慢性乙型肝炎对血清肝纤维化指标的影响。方法 对 40例慢性乙型肝炎服药0、3、6、9、12个月进行动态测定血清透明质酸 (HA)、层粘蛋白 (LN )、Ⅲ型前胶原 (PⅢP)和Ⅳ型胶原 (ⅣC)。结果 4项血清肝纤维化指标随着治疗时间延长不断下降 ,第 12个月时最明显 ,其中以HA最为显著 ,6个月复常率为 3 6.4% (8/2 2 ,P <0 .0 5 ) ,12个月复常率为 81.8% (18/ 2 2 ,P <0 .0 1) ,与ALT、AST复常率具有很好的相关性。按血清学疗效标准评价 ,6个月显效为 12 .5 % (5 / 40 ) ,有效为 12 .5 % (5 / 40 ) ,总有效率为 2 5 % (10 / 40 ) ;12个月显效为 42 .5 % (17/ 40 ,P <0 .0 5 ) ,有效为 2 7.5 % (11/ 40 ) ,总有效率为 70 % (2 8/ 40 ,P <0 .0 1)。结论拉米夫定治疗慢性乙型肝炎具有较好的近期抗肝纤维化作用。
Objective To observe the changes of fibrosis serum markers of the patients with chronic hepatitis B with lamivudine treatment. Methods Serum hyaluronic(HA)、laminin(LN)、type Ⅲ procollagen(PⅢP) and type Ⅳ collagen (ⅣC) were measured in forty patients by radioimmunoassay at 0, 3, 6, 9 and 12 months. Result Serum levels of HA、LN、 PⅢP and ⅣC were gradually decreased till the 12 month with treatment, especially HA. The correlation between serum HA and serum ALT and AST was good. The rates of efficacy were 25%(10/40) at 6 month and 70%(28/40, P < 0.01 ) at 12 mouth. Conclusion Lamivudine showed a beneficial effect on hepatic fibrosis patients with chronic hepatitis B.
出处
《肝脏》
2002年第4期251-252,共2页
Chinese Hepatology
